

1 Nasopharyngeal SARS-CoV2 viral loads in young children do not differ significantly from those
2 in older children and adults

3 Sharline Madera^{1*}, Emily Crawford^{2,3,4}, Charles Langelier^{1,2}, Nam K Tran⁵, Ed Thornborrow⁶,
4 Steve Miller⁶, Joseph L DeRisi^{2,4}

5
6 ¹ Department of Medicine, Division of Infectious Diseases

7 University of California, San Francisco, CA

8 ² Chan-Zuckerberg Biohub, San Francisco, CA

9 ³ Department of Microbiology and Immunology

10 University of California San Francisco, CA

11 ⁴ Department of Medicine and Biochemistry & Biophysics

12 University of California San Francisco, CA

13 ⁵ Department of Pathology and Laboratory Medicine

14 University of California, Davis School of Medicine, Sacramento, CA

15 ⁶ Department of Laboratory Medicine

16 University of California San Francisco, CA

17 *Corresponding author: sharline.madera@ucsf.edu

18

19

20

21 Abstract

22 The role of children in the spread of the SARS-CoV2 coronavirus has become a matter of urgent
23 debate as societies in the US and abroad consider how to safely reopen schools. Small studies
24 have suggested higher viral loads in young children. Here we present a multicenter investigation
25 on over five thousand SARS-CoV-2 cases confirmed by real-time reverse transcription (RT)
26 PCR assay. Notably, we found no discernable difference in amount of viral nucleic acid among
27 young children and adults.

28

29 Main


30 Children remain underrepresented in current studies aimed to analyze the spread of SARS-CoV2
31 coronavirus, making their contribution to viral transmission elusive. It is well established that, in
32 general, children experience less severe illness than do adults, though in rare cases children can
33 be subject to a severe multisystem inflammatory syndrome (1). And there is an emerging view
34 that children may play a lesser role in the spread of Coronavirus Disease 2019 (COVID-19) than
35 they do in other respiratory illnesses (2), but much uncertainty about this remains (3). Recently,
36 it was reported that children less than five years old may carry higher viral loads in the
37 nasopharynx than older children and adults (4), raising concerns that exposure to this group may
38 pose special epidemiologic risks. Here we report results bearing on this question from two
39 coronavirus testing laboratories that serve large populations of patients in California.

40

41 Laboratory A serves the UC San Francisco health care system, as well as local clinics and also
42 provides tests to the county health departments in 26 California counties. Laboratory B serves
43 principally the UC Davis health care system and partner clinics/hospitals centered in


44 Sacramento, CA. Both labs test similarly-collected nasopharyngeal swab specimens. Both
45 laboratories employed real-time RT-PCR SARS-CoV2 assays, and record for each positive
46 sample the cycle threshold (Ct) value. In general, primers from both the E and N genes are
47 employed, though in this analysis for simplicity we show only the E gene Ct values. For both
48 labs, we report the results of all specimens tested from March-August 2020. The population is
49 predominantly comprised of out-patients representing both symptomatic clinical cases and
50 asymptomatic cases identified by contact tracing.

51
52 Among 5,544 patients with laboratory-confirmed COVID-19 spanning Laboratory A and B, 199
53 children aged less than five years, 665 youth aged five to seventeen, and 4680 adults aged
54 eighteen and older, were identified. In order to ascertain potential differences in viral load
55 carriage, Ct values were queried across age groups. Ct values were used to approximately reflect
56 the viral load (inversely related to Ct value). As depicted in Figure 1, no significant differences
57 in Ct value were observed across the three groups. In particular, the children less than age 5 did
58 not display higher nasopharyngeal viral loads than older children or adults.



59

60 Figure 1a



61

62 Figure 1b.

63

64 Figure 1: Age distributed nasopharyngeal SARS-CoV2 viral nucleic acid content.

65 SARS-CoV2 viral nucleic acid detected by real-time RT-PCR in nasopharyngeal swabs from

66 patients infected with SARS-CoV-2 as detected by (a) laboratory A (N= 4,619, ANOVA p =

67 0.18) and (b) laboratory B (N= 925, ANOVA p= 0.073). Data are stratified by three age groups,

68 ages <5; 5-17; 18 and older.

69

70 In contrast to a prior smaller study (4), we do not observe higher nasopharyngeal viral loads in
71 children below the age of 5 years. The population studied is largely reflective of asymptomatic
72 and mildly symptomatic individuals, and notably does not include patients hospitalized with
73 severe disease. Thusly, these conclusions apply primarily to the outpatient setting and may not
74 extend to the severely-ill. There are conflicting data on the association of viral load with disease
75 severity, with some studies showing higher viral loads in severe cases (5), while others indicate a
76 lower viral load in hospitalized patients than those not hospitalized (6). Since the viral load
77 changes rapidly during early infection, the time between symptom onset and sampling is a
78 significant variable. Some patients with severe disease may delay entry to care, missing the peak
79 period of viral shedding. Notably, these earlier studies were done primarily in the hospital
80 setting, so the findings do not necessarily translate to the outpatient population. Nevertheless, the
81 robust sample size of 5,544 patients presented in this work, including close to 200 children aged
82 less than 5 years, is more likely to be representative of the general population of infected
83 subjects. An accurate understanding of the variables that affect viral transmission, including
84 amount of virus carriage, will be essential to guide public policy efforts as re-opening strategies
85 are devised.

86

87 We caution, however, that viral load as determined by RT-PCR is only one of many potential
88 influences on infectivity. PCR accurately enumerates viral genomes, but does not indicate
89 whether they come from infectious virions, defective viral particles, or lysed infected cells.
90 Infectivity in populations is affected by many other clinical, behavioral and environmental
91 factors. Our findings argue against the idea that young children are more infectious due to higher

92 viral loads, and suggest an alternative explanation for their contribution to SARS-CoV2
93 transmission, such as representing a reservoir of asymptomatic infections. Ultimately, the role of
94 young children in the spread of SARS-CoV2 can only be determined by careful clinical and
95 epidemiological studies that examine transmission events in the population.

96

97 Method

98 Real time RT-PCR assay for SARS-CoV-2 RNA

99 Nasopharyngeal swabs collected into DNA/RNA Shield (Laboratory A) or viral transport media
100 (Laboratory B) were obtained from patients. At Laboratory A, samples were subjected to a
101 clinically reportable Laboratory Developed Test (LDT) consisting of total nucleic acid extraction
102 using the Zymo Quick-DNA/RNA Viral Magbead kit (Zymo Research, Orange CA) and real-
103 time RT-PCR using the NEB Luna Universal RT-qPCR kit (New England Biolabs, Ipswich
104 MA) on Bio-Rad CFX384 instruments (Bio-Rad, Hercules, CA). At Laboratory B, automated
105 nucleic extraction and real-time RT-PCR testing was performed on the Roche cobas 6800
106 (Roche Diagnostics, Indianapolis, IN) using the EUA SARS-CoV-2 assay. Each real-time RT-
107 PCR assay provided a threshold cycle (Ct) value, indicating the number of cycles surpassing the
108 threshold for a positive test. Samples were considered positive if the Ct value was ≤ 40 , and
109 otherwise it was negative.

110

111 Statistics

112 A one-way analysis of variance was used to compare Ct values across age groups of samples
113 positive for COVID-19 infection with R ggpubr v.0.4.0.

114

115 Data Availability

116 The data shown in the manuscript are available upon request from the corresponding author.

117

118 REFERENCES

119 1. Hoang A. et al. COVID-19 in 7780 pediatric patients: A systematic review. *E Clinical*
120 *Medicine*. <https://doi.org/10.1016/eclinm.2020.100433> (2020)

121 2. Rajmil, L. Role of children in the transmission of the COVID-19 pandemic: a rapid
122 scoping review. *BMJ Pediatrics* [https:// doi: 10.1136/bmjpo-2020-000722](https://doi.org/10.1136/bmjpo-2020-000722) (2020)

123 3. Mallapaty, S. How do children spread the coronavirus? The science still isn't clear.
124 *Nature* **581**, 127-128. (2020)

125 4. Heald-Sargent T. et al. Age-Related Differences in Nasopharyngeal Severe Acute
126 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to
127 Moderate Coronavirus Disease 2019 (COVID-19). *JAMA*
128 *Pediatr*. <https://doi:10.1001/jamapediatrics.2020.3651> (2020)

129 5. Liu, Y. et al. Viral dynamics in mild and severe cases of COVID-19. *The Lancet*
130 *Infectious Diseases*. **20(6)**, 656-657. (2020)

131 6. Argyropoulos K.V. et al. Association of Initial Viral Load in Severe Acute Respiratory
132 Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms. *Am J*
133 *Pathol*. **190(9)**,1881-1887. (2020)

134

135

136

137

138 Acknowledgements

139 This work was funded by the Chan Zuckerberg Biohub. We greatly appreciate the guidance Don

140 Ganem in the preparation of this manuscript.

141

142 Author information

143 Affiliations

144 Department of Medicine, Division of Infectious Diseases, University of California, San

145 Francisco, CA

146 Sharline Madera

147

148 Chan-Zuckerberg Biohub, San Francisco, CA

149 Emily Crawford, Joseph L DeRisi

150

151 Department of Microbiology and Immunology, University of California San Francisco, CA

152 Emily Crawford

153

154 Department of Medicine and Biochemistry & Biophysics, University of California San

155 Francisco, CA

156 Emily Crawford, Joseph L DeRisi

157

158 Department of Pathology and Laboratory Medicine, University of California, Davis School of

159 Medicine, Sacramento, CA

160 Nam K Tran

161
162 Department of Laboratory Medicine, University of California San Francisco, CA
163 Ed Thornborrow, Steve Miller
164
165 Contributions
166 E.C., E.T., J.L.D., N.T. contributed to study design. S. Madera, E.C., J.L.D., and N.T.
167 contributed to collection of data. S. Madera contributed to data analysis. S. Madera, E.C., N.T.,
168 J.L.D., and S. Miller contributed to manuscript preparation. All authors approved the manuscript.
169
170 Corresponding authors
171 Correspondence to Sharline Madera.
172
173 Ethics Declaration
174 Competing Interests
175 Nam Tran is a consultant for Roche Diagnostics. UC Davis Health is a designated Roche
176 Molecular Center of Excellence.